Benefit of Treatment Individualization in Patients with Chronic Hepatitis C Receiving Peginterferon Alfa-2a and Ribavirin in a Large Noninterventional Cohort Study

• Wolf Peter Hofmann,

  Affiliation Practice of Gastroenterology, Berlin, Germany

  ⨯
• Stefan Mauss,

  Affiliation Center for HIV and Hepatogastroenterology, Düsseldorf, Germany

  ⨯
• Thomas Lutz,

  Affiliation Infektiologikum, Frankfurt, Germany

  ⨯
• Andreas Schober,

  Affiliation Practice of Hepatology, Göttingen, Germany

  ⨯
• Klaus Böker,

  Affiliation Practice of Hepatology, Hannover, Germany

  ⨯
• Gero Moog,

  Affiliation Practice of Gastroenterology, Kassel, Germany

  ⨯
• Axel Baumgarten,

  Affiliation Center of Infectious Diseases, Berlin, Germany

  ⨯
• Heike Pfeiffer-Vornkahl,

  Affiliation Institute for Clinical Research and Statistics, Offenbach, Germany

  ⨯
• Ulrich Alshuth,

  Affiliation Virology, Roche Pharma AG, Grenzach-Wyhlen, Germany

  ⨯
• Dietrich Hüppe,

  Affiliation Center of Gastroenterology, Herne, Germany

  ⨯
• Heiner Wedemeyer,

  Affiliation Department of Gastroenterology, Hepatology, and Endocrinology, Medizinische Hochschule Hannover, Hannover, Germany

  ⨯
• Michael P. Manns,

  Affiliation Department of Gastroenterology, Hepatology, and Endocrinology, Medizinische Hochschule Hannover, Hannover, Germany

  ⨯
• Eckart Schott

  * E-mail: eckart.schott@charite.de

  Affiliation Dept. of Hepatology and Gastroenterology, Charité Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany

  ⨯